Research Paper Volume 13, Issue 12 pp 16248—16266

Pan-cancer analysis reveals an immunological role and prognostic potential of PXN in human cancer

Phosphorylation analysis of the PXN protein in different cancers. Using the CPTAC dataset, we analyzed the expression level of PXN phosphoproteins (S135, S137, S258, S272, S303, S106, Y118, T263, S340, S143, S136, S547, S533, S272, S103, S85, S302, and S109 sites) between normal tissue and primary tissue of selected tumors with UALCAN. (A) Schematic diagram of PXN protein showing phosphoprotein sites with positive results. Box plots are shown for different cancers: (B) UCEC, (C) breast cancer, (D) lung adenocarcinoma, (E) RCC, (F) ovarian cancer, and (G) colon cancer.

Figure 5. Phosphorylation analysis of the PXN protein in different cancers. Using the CPTAC dataset, we analyzed the expression level of PXN phosphoproteins (S135, S137, S258, S272, S303, S106, Y118, T263, S340, S143, S136, S547, S533, S272, S103, S85, S302, and S109 sites) between normal tissue and primary tissue of selected tumors with UALCAN. (A) Schematic diagram of PXN protein showing phosphoprotein sites with positive results. Box plots are shown for different cancers: (B) UCEC, (C) breast cancer, (D) lung adenocarcinoma, (E) RCC, (F) ovarian cancer, and (G) colon cancer.